• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Compliance and Quality
    • Careers
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • In the News
    • Publications
  • Contact Us

Publications

As of January 1, 2024, Sonata will have a new Category I CPT® code, 58580 (Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency).

The temporary Category III code 0404T (Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency) will be deleted and no longer accepted as of January 1, 2024.

KEY PUBLICATIONS

SONATA Pivotal IDE Trial: 3-Year Results

Lukes A, Green MA. Three-Year Results of the SONATA Pivotal Trial of Transcervical Fibroid Ablation for Symptomatic Uterine Myomata. J Gynecol Surg. 2020;36:5, 228-233.

SONATA Pivotal IDE Trial: 12-Month Results (FDA Submission)

Chudnoff S, Guido R, Roy K, Levine D, Mihalov L, Garza-Leal JG. Ultrasound-Guided Transcervical Ablation of Uterine Leiomyomas: The SONATA Trial. Obstet Gynecol. 2019; 133(1): 13-22.

Garza-Leal JG. Long-Term Clinical Outcomes of Transcervical Radiofrequency Ablation of Uterine Fibroids: The VITALITY Study. Journal of Gynecologic Surgery. 2019; 35:19-23.

Brölmann H, Bongers M, Garza-Leal J, Gupta J, et al. The FAST-EU trial: 12-month clinical outcomes of women after intrauterine sonography-guided transcervical radiofrequency ablation of uterine fibroids. Gynecol Surg. 2016; 13: 27-35.

Additional Selected Clinical Publications

Roy K, Robinson JK. Durable Improvement in Generic and Fibroid-Specific Quality of Life in Women Treated with Transcervical Fibroid Ablation with the Sonata System After Three Years. J Gynecol Surg. 2022 Apr 1;38(2):143-147.

Lindner, L.H., Roy, K. & Toub, D.B. Transcervical Fibroid Ablation (TFA) with the Sonata System: Updated Review of a New Paradigm for Myoma Treatment. Curr Obstet Gynecol Rep 11, 238–248 (2022).

Arnreiter C, Oppelt P. A Systematic Review of the Treatment of Uterine Myomas Using Transcervical Ultrasound-Guided Radiofrequency Ablation with the Sonata System. Journal of Minimally Invasive Gynecology. 2021 Aug;28(8):1462-1469.

Römer T, Bends R, Christoffel L, et al. Treatment of Symptomatic Fibroids with Transcervical Ultrasound-guided Radiofrequency Ablation. Indication, procedure, results, and complications—2020 expert consensus. Part 2: Transcervical Radiofrequency Ablation (TRFA)–Methods, indications, results, and comparison with other therapies. Frauenarzt. 2021;162-168.*

Christoffel L, Römer T, Schiermeier S. Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE): Study Protocol and Preliminary Results. Med Devices (Auckl). 2021;14:77-84.

Shifrin G, Engelhardt M, Gee P, Pschadka G. Transcervical fibroid ablation with the Sonata® system for treatment of submucous and large uterine fibroids. Int J Gynaecol Obstet. 2021;79-85.

Taheri M, Galo L, Potts C, Sakhel K, Quinn SD. Nonresective treatments for uterine fibroids: a systematic review of uterine and fibroid volume reductions. International Journal of Hyperthermia. 2019; 1-7.

Huirne J, Brooks E. Improvement in health utility after transcervical radiofrequency ablation of uterine fibroids with the Sonata System: Health utility after radiofrequency ablation. Eur J Obstet Gynecol Reprod Biol. 2018; 224: 175-180.

Toub, DB. A New Paradigm for Uterine Fibroid Treatment: Transcervical, Intrauterine Sonography-Guided Radiofrequency Ablation of Uterine Fibroids with the Sonata System. Curr Obstet Gynecol Rep. 2017;6(1):67-73.

Bongers M, Brölmann H, Gupta J, Garza-Leal JG, Toub D. Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate® System: three- and six-month endpoint results from the FAST-EU study. Gynecol Surg. 2015;12(1):61-70.

Jones, S., O'Donovan, P, Toub, D, Radiofrequency Ablation for Treatment of Symptomatic Uterine Fibroids. Obstet Gynecol Int.  2012;194839.

Garza-Leal, JG, Toub, D, León, IH, et al. Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate System: safety, tolerability, and ablation results in a closed abdomen setting. Gynecol Surg. 2011; 8: 327.

 

*Translated from original German publication.  Römer T, Bends R, Christoffel L, et al. Behandlung von symptomatischen Myomen mit der transzervikalen ultraschallgesteuerten Radiofrequenzablation-Indikationen, Durchführung, Ergebnisse und Komplikationen-Expertenkonsensus 2020. Teil 2: Die transzervikale Radiofrequenzablation (TRFA) – Methode, Indikationen, Ergebnisse und Vergleich mit anderen Therapien. Frauenarzt. 2021;162-168.

Primary Sidebar

  • Privacy Notice
  • Cookie Notice
  • Do Not Sell/Share My Personal Information
  • Limit the Use of My Sensitive Personal Information
  • Terms of Use
  • Impressum
  • Patents
  • Safety Information

© Copyright 2025 Gynesonics · All Rights Reserved · WS 05198 Rev. M

  • Privacy Notice
  • Cookie Notice
  • Do Not Sell/Share My Personal Information
  • Limit the Use of My Sensitive Personal Information
  • Terms of Use
  • Impressum
  • Patents
  • Safety Information